Nima Farzan was appointed to be Latigo's CEO on July 22. (courtesy photo) The success of the Conejo Valley’s burgeoning biotechnology and life sciences scene was boosted after Thousand Oaks-based Latigo Biotherapeutics, in its Aug. 6 initial public offering, raised $345.6 million, exceeding its initial fundraising expectations. Originally, the company expected to offer 16 million shares between $16…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
